Breast cancer is one of the most common malignancies among women worldwide. Luminal A is a prevalent molecular subtype of breast cancer, and doxorubicin is one of the chemotherapeutic agents used in its treatment. However, reduced sensitivity to chemotherapy remains a challenge. Insulin may promote cancer cell survival and potentially influence the cytotoxic effects of anticancer agents. This study aimed to investigate the effect of insulin supplementation on doxorubicin-induced cell death in T-47D luminal A breast cancer cells. An in vitro experimental study was conducted using T-47D cells treated with doxorubicin at concentrations of 3.13, 6.25, 12.5, 25, 50, and 100 μg/mL, with and without insulin supplementation. Cell viability was assessed using the MTT assay, and cell death was estimated from the assay results. Data were analyzed using a paired-samples t-test to compare treatment groups and linear regression to evaluate the relationship between doxorubicin concentration and the percentage of cell death. The results showed that the percentage of cell death increased with increasing doxorubicin concentrations. However, insulin-supplemented cells consistently exhibited lower percentages of cell death than cells treated with doxorubicin alone across all tested concentrations. These findings suggest that insulin supplementation is associated with reduced doxorubicin-induced cytotoxicity in T-47D breast cancer cells. Further studies are needed to clarify the underlying mechanisms and determine whether this effect contributes to reduced chemotherapy sensitivity.